Clinical Trials Browser

Phase 4 × Withdrawn × pembrolizumab × Clear all

NCT03891979 2020-06-26

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

Phase 4 Withdrawn

Gastrointestinal

Pancreatic Neoplasms